Tag Archives: GWPH

Marijuana Index Dips 3% in June as Canadian Stocks Continue to Decline

Marijuana Index Dips 3% in June as Canadian Stocks Continue to Decline

Marijuana Index Dips 3% in June as Canadian Stocks Continue to Decline

The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, decreased 3% in June as continued losses in Canada closed out the Index’s second worst performing quarter since its inception in January 2015.

GWPH Phase 3 Results

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology

LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome

LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.

https://marijuanaindex.com/stock-quotes/north-american-marijuana-index/

A Survey Of The North American Marijuana Index - Part One

In this survey we will be reviewing the stocks that make up the North American Marijuana Index. In Part 1, we’ll look at Canopy Growth Corp. (OTCPK:TWMJF), GW pharmaceuticals (NASDAQ:GWPH), Axim Biotechnologies Inc. (OTCQB:AXIM), and United Cannabis Corp. (OTCQB:CNAB).

Mentor Capital

Mentor Capital Acquires $1.0 Million of GW Pharmaceuticals, Plc

SAN DIEGO, Calif., March 3, 2017/Weed Wire/ — Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.

GWPH Phase 3 Results

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.

Institutional Cannabis: Defining Institutional Stakeholders

Institutional Cannabis: Defining Institutional Stakeholders

For the purpose of this column we consider three types of institutions: government, academic and corporate. They are the thought leaders, market leaders and mainstream actors from outside the industry that are stakeholders in the effects of an economic outcome.

GWPH Phase 3 Results

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome

LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.

GWPH Riding High: Stock Rises on Clinical Trial's Positive Results

GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results

On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.

Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches - Sources

Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches - Sources

GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

LONDON, Sept. 7, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress

LONDON, Aug. 9, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended 30 June 2016.

GWPH Phase 3 Results

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

LONDON, July 18, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market.

Georgia’s Medical Marijuana Law Just Turned One Year Old

Georgia’s Medical Marijuana Law Just Turned One Year Old

The phones at the Georgia Department of Public Health no longer ring off the hook with people calling to find doctors or asking questions about how the state’s medical marijuana registry works.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, June 27, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

GWPH Phase 3 Results

GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)

LONDON, June 21, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (“GW” or “the Company”) today announced that the Company has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May

LONDON, May 16, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress

LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May

LONDON, May 4, 2016 /Weed Wire/ — GW Pharmaceuticals announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.

Epidiolex in Utah

Epidiolex in Utah: Decrease in Seizure Frequency and Severity

In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).

GWPH Phase 3 Results

GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex

LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.

GW Pharma

GW Pharma Reports Positive Results and Stock More than Doubles by Mid-Day

On March 14, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for the first pivotal Phase 3 study of Epidiolex, a CBD-based medicine, in treating Dravet syndrome, a severe form of pediatric epilepsy.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)

LONDON, March 14, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome.

Don't Fight the Tape

Don’t Fight the Tape: Cannabis Stocks Subject to Broad Market Swings

Investors may be lulled into thinking that stocks they own or study in the cannabis space are insulated from what’s happening in the broader market. But that’s simply not true, and violates one of the oldest maxims in investing: Don’t fight the tape.

GWPH

GWPH Business Plan: Alan Brochstein’s Thoughts

Alan Brochstein has followed quite closely recent developments in the medical and financial world insofar as they have affected GW Pharmaceuticals (NASDAQ: GWPH), the developer of two promising cannabis-based medications.

market

Are Cannabis Stocks Riding a Market Wave?

In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.

stock forecast

What the 5 Largest Cannabis Stocks Can Tell Us

The early leaders in market cap (the total value of publicly-traded equity) in a expanding industry like cannabis can tell us a lot. These companies have a lot of advantages by being on this perch, but also some responsibilities.


Page 1 of 212
Top